Louisa W Whitesides1, Jill M Baren2, Michelle H Biros3, Ross J Fleischman4, Prasanthi R Govindarajan5, Elizabeth B Jones6, Arthur M Pancioli7, Rebecca D Pentz8, Victoria M Scicluna9, David W Wright10, Neal W Dickert11,12. 1. 1 Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 2. 2 Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3. 3 Hennepin County Medical Center, Department of Emergency Medicine, School of Medicine, University of Minnesota, Minneapolis, MN, USA. 4. 4 Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA. 5. 5 Department of Emergency Medicine, School of Medicine, University of California San Francisco, San Francisco, CA, USA. 6. 6 Department of Emergency Medicine, University of Texas Medical School at Houston, Houston, TX, USA. 7. 7 Department of Emergency Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. 8. 8 Department of Hematology and Oncology, School of Medicine, Emory University, Atlanta, GA, USA. 9. 9 School of Medicine, Emory University, Atlanta, GA, USA. 10. 10 Department of Emergency Medicine, School of Medicine, Emory University, Atlanta, GA, USA. 11. 11 Division of Cardiology, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA. 12. 12 Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Abstract
BACKGROUND: Evidence suggests that patients are generally accepting of their enrollment in trials for emergency care conducted under exception from informed consent. It is unknown whether individuals with more severe initial injuries or worse clinical outcomes have different perspectives. Determining whether these differences exist may help to structure post-enrollment interactions. METHODS: Primary clinical data from the Progesterone for the Treatment of Traumatic Brain Injury trial were matched to interview data from the Patients' Experiences in Emergency Research-Progesterone for the Treatment of Traumatic Brain Injury study. Answers to three key questions from Patients' Experiences in Emergency Research-Progesterone for the Treatment of Traumatic Brain Injury study were analyzed in the context of enrolled patients' initial injury severity (initial Glasgow Coma Scale and Injury Severity Score) and principal clinical outcomes (Extended Glasgow Outcome Scale and Extended Glasgow Outcome Scale relative to initial injury severity). The three key questions from Patients' Experiences in Emergency Research-Progesterone for the Treatment of Traumatic Brain Injury study addressed participants' general attitude toward inclusion in the Progesterone for the Treatment of Traumatic Brain Injury trial (general trial inclusion), their specific attitude toward being included in Progesterone for the Treatment of Traumatic Brain Injury trial under the exception from informed consent (personal exception from informed consent enrollment), and their attitude toward the use of exception from informed consent in the Progesterone for the Treatment of Traumatic Brain Injury trial in general (general exception from informed consent enrollment). Qualitative analysis of interview transcripts was performed to provide contextualization and to determine the extent to which respondents framed their attitudes in terms of clinical experience. RESULTS: Clinical data from Progesterone for the Treatment of Traumatic Brain Injury trial were available for all 74 patients represented in the Patients' Experiences in Emergency Research-Progesterone for the Treatment of Traumatic Brain Injury study (including 46 patients for whom the surrogate was interviewed due to the patient's cognitive status or death). No significant difference was observed regarding acceptance of general trial inclusion or acceptance of general exception from informed consent enrollment between participants with favorable neurological outcomes and those with unfavorable outcomes relative to initial injury. Agreement with personal enrollment in Progesterone for the Treatment of Traumatic Brain Injury trial under exception from informed consent, however, was significantly higher among participants with favorable outcomes compared to those with unfavorable outcomes (89% vs 59%, p = 0.003). There was also a statistically significant relationship between more severe initial injury and increased acceptance of personal exception from informed consent enrollment ( p = 0.040) or general exception from informed consent use ( p = 0.034) in Progesterone for the Treatment of Traumatic Brain Injury trial. Many individuals referenced personal experience as a basis for their attitudes, but these references were not used to support negative views. CONCLUSION: Patients and surrogates of patients with unfavorable clinical outcomes were somewhat less accepting of their own inclusion in the Progesterone for the Treatment of Traumatic Brain Injury trial under exception from informed consent than were patients or surrogates of patients with favorable clinical outcomes. These findings suggest a need to identify optimal strategies for communicating with patients and their surrogates regarding exception from informed consent enrollment when clinical outcomes are poor.
BACKGROUND: Evidence suggests that patients are generally accepting of their enrollment in trials for emergency care conducted under exception from informed consent. It is unknown whether individuals with more severe initial injuries or worse clinical outcomes have different perspectives. Determining whether these differences exist may help to structure post-enrollment interactions. METHODS: Primary clinical data from the Progesterone for the Treatment of Traumatic Brain Injury trial were matched to interview data from the Patients' Experiences in Emergency Research-Progesterone for the Treatment of Traumatic Brain Injury study. Answers to three key questions from Patients' Experiences in Emergency Research-Progesterone for the Treatment of Traumatic Brain Injury study were analyzed in the context of enrolled patients' initial injury severity (initial Glasgow Coma Scale and Injury Severity Score) and principal clinical outcomes (Extended Glasgow Outcome Scale and Extended Glasgow Outcome Scale relative to initial injury severity). The three key questions from Patients' Experiences in Emergency Research-Progesterone for the Treatment of Traumatic Brain Injury study addressed participants' general attitude toward inclusion in the Progesterone for the Treatment of Traumatic Brain Injury trial (general trial inclusion), their specific attitude toward being included in Progesterone for the Treatment of Traumatic Brain Injury trial under the exception from informed consent (personal exception from informed consent enrollment), and their attitude toward the use of exception from informed consent in the Progesterone for the Treatment of Traumatic Brain Injury trial in general (general exception from informed consent enrollment). Qualitative analysis of interview transcripts was performed to provide contextualization and to determine the extent to which respondents framed their attitudes in terms of clinical experience. RESULTS: Clinical data from Progesterone for the Treatment of Traumatic Brain Injury trial were available for all 74 patients represented in the Patients' Experiences in Emergency Research-Progesterone for the Treatment of Traumatic Brain Injury study (including 46 patients for whom the surrogate was interviewed due to the patient's cognitive status or death). No significant difference was observed regarding acceptance of general trial inclusion or acceptance of general exception from informed consent enrollment between participants with favorable neurological outcomes and those with unfavorable outcomes relative to initial injury. Agreement with personal enrollment in Progesterone for the Treatment of Traumatic Brain Injury trial under exception from informed consent, however, was significantly higher among participants with favorable outcomes compared to those with unfavorable outcomes (89% vs 59%, p = 0.003). There was also a statistically significant relationship between more severe initial injury and increased acceptance of personal exception from informed consent enrollment ( p = 0.040) or general exception from informed consent use ( p = 0.034) in Progesterone for the Treatment of Traumatic Brain Injury trial. Many individuals referenced personal experience as a basis for their attitudes, but these references were not used to support negative views. CONCLUSION:Patients and surrogates of patients with unfavorable clinical outcomes were somewhat less accepting of their own inclusion in the Progesterone for the Treatment of Traumatic Brain Injury trial under exception from informed consent than were patients or surrogates of patients with favorable clinical outcomes. These findings suggest a need to identify optimal strategies for communicating with patients and their surrogates regarding exception from informed consent enrollment when clinical outcomes are poor.
Entities:
Keywords:
Research ethics; acute care research; bioethics; emergency research; informed consent; traumatic brain injury
Authors: Gerald van Belle; Spyros D Mentzelopoulos; Tom Aufderheide; Susanne May; Graham Nichol Journal: Resuscitation Date: 2014-12-15 Impact factor: 5.262
Authors: David W Wright; Sharon D Yeatts; Robert Silbergleit; Yuko Y Palesch; Vicki S Hertzberg; Michael Frankel; Felicia C Goldstein; Angela F Caveney; Harriet Howlett-Smith; Erin M Bengelink; Geoffrey T Manley; Lisa H Merck; L Scott Janis; William G Barsan Journal: N Engl J Med Date: 2014-12-10 Impact factor: 91.245
Authors: Neal W Dickert; Victoria A Mah; Jill M Baren; Michelle H Biros; Prasanthi Govindarajan; Arthur Pancioli; Robert Silbergleit; David W Wright; Rebecca D Pentz Journal: Resuscitation Date: 2013-04-16 Impact factor: 5.262
Authors: Jan Lecouturier; Helen Rodgers; Gary A Ford; Tim Rapley; Lynne Stobbart; Stephen J Louw; Madeleine J Murtagh Journal: BMC Med Ethics Date: 2008-04-29 Impact factor: 2.652
Authors: Maria J Robinson; Jodi Taylor; Stephen J Brett; Jerry P Nolan; Matthew Thomas; Barnaby C Reeves; Chris A Rogers; Sarah Voss; Madeleine Clout; Jonathan R Benger Journal: Trials Date: 2019-02-08 Impact factor: 2.279
Authors: Neal W Dickert; Victoria M Scicluna; Opeolu Adeoye; Dominick J Angiolillo; James C Blankenship; Chandan M Devireddy; Michael R Frankel; Sara F Goldkind; Gautam Kumar; Yi-An Ko; Andrea R Mitchell; Raul G Nogueria; Ruth M Parker; Manesh R Patel; Michele Riedford; Robert Silbergleit; Candace D Speight; Ilana Spokoyny; Kevin P Weinfurt; Rebecca D Pentz Journal: J Am Heart Assoc Date: 2019-01-22 Impact factor: 5.501
Authors: Insiyah Campwala; Francis X Guyette; Joshua B Brown; Peter W Adams; Barbara J Early; Mark H Yazer; Matthew D Neal; Brian S Zuckerbraun; Jason L Sperry Journal: BMC Emerg Med Date: 2020-10-01